Marios Zouridakis

Dr. Marios Zouridakis


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
Marios ZouridakisMarios Zouridakis
Marios Zouridakis
Athanasios PapakyriakouAthanasios Papakyriakou
Athanasios Papakyriakou
IIIgor A. Ivanov
Igor A. Ivanov
IKIgor E. Kasheverov
Igor E. Kasheverov
VTVictor Tsetlin
Victor Tsetlin
PGPetros Giastas
Petros Giastas
The α9 subunit of nicotinic acetylcholine receptors (nAChRs) exists mainly in heteropentameric assemblies with α10. Accumulating data indicate the presence of three different binding sites in α9α10 nAChRs: the α9(+)/α9(−), the α9(+)/α10(−), and the α10(+)/α9(−). The major role of the principal (+) side of the extracellular domain (ECD) of α9 subunit in binding of the antagonists methyllylcaconitine and α-bungarotoxin was shown previously by the crystal structures of the monomeric α9-ECD with these molecules. Here we present the 2.26-Å resolution crystal structure of α9-ECD in complex with α-conotoxin (α-Ctx) RgIA, a potential drug for chronic pain, the first structure reported for a complex between an nAChR domain and an α-Ctx. Superposition of this structure with those of other α-Ctxs bound to the homologous pentameric acetylcholine binding proteins revealed significant similarities in the orientation of bound conotoxins, despite the monomeric state of the α9-ECD. In addition, ligand-binding studies calculated a binding affinity of RgIA to the α9-ECD at the low micromolar range. Given the high identity between α9 and α10 ECDs, particularly at their (+) sides, the presented structure was used as template for molecular dynamics simulations of the ECDs of the human α9α10 nAChR in pentameric assemblies. Our results support a favorable binding of RgIA at α9(+)/α9(−) or α10(+)/α9(−) rather than the α9(+)/α10(−) interface, in accordance with previous mutational and functional data.


17 July 2006 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
KKKalliopi Kostelidou
Kalliopi Kostelidou
NTNikolaos Trakas
Nikolaos Trakas
Marios ZouridakisMarios Zouridakis
Marios Zouridakis
KBKalliopi Bitzopoulou
Kalliopi Bitzopoulou
ASAlexandros Sotiriadis
Alexandros Sotiriadis
STSocrates J. Tzartos
Socrates J. Tzartos
The nicotinic acetylcholine receptor (AChR) is a ligand-gated ion channel found in muscles and neurons. Muscle AChR, formed by five homologous subunits (α2βγδ or α2βγε), is the major antigen in the autoimmune disease, myasthenia gravis (MG), in which pathogenic autoantibodies bind to, and inactivate, the AChR. The extracellular domain (ECD) of the human muscle α subunit has been heterologously expressed and extensively studied. Our aim was to obtain satisfactory amounts of the ECDs of the non-α subunits of human muscle AChR for use as starting material for the determination of the 3D structure of the receptor ECDs and for the characterization of the specificities of antibodies in sera from patients with MG. We expressed the N-terminal ECDs of the β (amino acids 1–221; β1–221), γ (amino acids 1–218; γ1–218), and ε (amino acids 1–219; ε1–219) subunits of human muscle AChR in the yeast, Pichia pastoris. β1–221 was expressed at ≈ 2 mg·L−1 culture, whereas γ1–218 and ε1–219 were expressed at 0.3–0.8 mg·L−1 culture. All three recombinant polypeptides were glycosylated and soluble; β1–221 was mainly in an apparently dimeric form, whereas γ1–218 and ε1–219 formed soluble oligomers. CD studies of β1–221 suggested that it has considerable β-sheet secondary structure with a proportion of α-helix. Conformation-dependent mAbs against the ECDs of the β or γ subunits specifically recognized β1–221 or γ1–218, respectively, and polyclonal rabbit antiserum raised against purified β1–221 bound to 125I-labeled α-bungarotoxin-labeled human AChR. Moreover, immobilization of each ECD on Sepharose beads and incubation of the ECD–Sepharose matrices with MG sera caused a significant reduction in the concentrations of autoantibodies in the sera, showing specific binding to the recombinant ECDs. These results suggest that the expressed proteins present some near-native conformational features and are thus suitable for our purposes.

1 November 2015 in International Immunopharmacology
Verified
Journal Article
Closed access
OLOlena Lykhmus
Olena Lykhmus
GGGalyna Gergalova
Galyna Gergalova
Marios ZouridakisMarios Zouridakis
Marios Zouridakis
STSocrates Tzartos
Socrates Tzartos
SKSergiy Komisarenko
Sergiy Komisarenko
MSMaryna Skok
Maryna Skok

3 May 2024 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
HRHarry Ridgway
Harry Ridgway
GMGraham J. Moore
Graham J. Moore
LGLaura Kate Gadanec
Laura Kate Gadanec
AZAnthony Zulli
Anthony Zulli
Vasso ApostolopoulosVasso Apostolopoulos
Vasso Apostolopoulos
John MatsoukasJohn Matsoukas
John Matsoukas
Pre-existing hypertensive pathologies are linked to worsened outcomes in patients infected with severe-acute respiratory syndrome (SARS-CoV-2). Sartans, a family of anti-hypertensive angiotensin receptor blockers (ARBs), reduce morbidity and mortality in coronavirus 2019 patients by aeffecting angiotensin-converting enzyme-2 (ACE2). The purpose of this study was to determine the anti-SARS-CoV-2viral and antihypertensive abilities of nirmatrelvir, and commercially available (e.g. candesartan, losartan, and losartan carboxylic (Exp3174))) and newly synthesized sartans (e.g. benzimidazole-N-biphenyl carboxyl (ACC519C), and benzimidazole-N-biphenyl tetrazole (ACC519T)), compared to nirmatrelvir, the antiviral component of paxlovid. Surface plasmon resonance-binding (SPR) and enzymatic studies were used to determine drug effect on ACE2, antiviral abilities were evaluated using Vero E6 cells infected with SARS-CoV-2 and antihypertensive effects were investigated using rabbit iliac arteries contracted to angiotensin II-dose response. The antiviral activity of benzimidazole-based candesartan and ACC519C were equipotent with nirmatrelvir (95% inhibition), while the imidazole-based losartan and E×p3174and ACC519T were less potent (75-80 and 50%, respectively%) and E×p3174was the least effective (50%). Furthermore, SPR analysis revealed a high binding affinity of sartans for ACE2 protein. Moreover, candesartan and nirmatrelvir exhibited the greatest inhibitory and cytopathic effect (3.96%) when given in combination rather than individually (6.10% and 5.08%, respectively). In addition,The ACE2 enzymatic activity assays demonstrated enhancement or inhibition properties of novel sartans toward ACE2 enzyme. Lastly, ACC519T potently reduced angiotensin II-mediated contraction while nirmatrelvir and ACC519T(2) had no effect. This study describes the discovery of a new class of benzimidazole-based sartans that drastically inhibit SARS-CoV-2, which could be attributed, at least in part, to their interaction with ACE2.

22 November 2018 in Marine Drugs
Verified
Journal Article
Open access
PDF file
ЕКЕлена Крюкова
Елена Крюкова
IIIgor Ivanov
Igor Ivanov
DLDmitry Lebedev
Dmitry Lebedev
ESEkaterina Spirova
Ekaterina Spirova
NENatalya S. Egorova
Natalya S. Egorova
VTVictor Tsetlin
Victor Tsetlin
α-Conotoxins from Conus snails are capable of distinguishing muscle and neuronal nicotinic acetylcholine receptors (nAChRs). α-Conotoxin RgIA and αO-conotoxin GeXIVA, blocking neuronal α9α10 nAChR, are potential analgesics. Typically, α-conotoxins bind to the orthosteric sites for agonists/competitive antagonists, but αO-conotoxin GeXIVA was proposed to attach allosterically, judging by electrophysiological experiments on α9α10 nAChR. We decided to verify this conclusion by radioligand analysis in competition with α-bungarotoxin (αBgt) on the ligand-binding domain of the nAChR α9 subunit (α9 LBD), where, from the X-ray analysis, αBgt binds at the orthosteric site. A competition with αBgt was registered for GeXIVA and RgIA, IC50 values being in the micromolar range. However, high nonspecific binding of conotoxins (detected with their radioiodinated derivatives) to His6-resin attaching α9 LBD did not allow us to accurately measure IC50s. However, IC50s were measured for binding to Aplysia californica AChBP: the RgIA globular isomer, known to be active against α9α10 nAChR, was more efficient than the ribbon one, whereas all three GeXIVA isomers had similar potencies at low µM. Thus, radioligand analysis indicated that both conotoxins can attach to the orthosteric sites in these nAChR models, which should be taken into account in the design of analgesics on the basis of these conotoxins.